Viewing Study NCT02464657

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:35 PM
Ignite Modification Date: 2026-03-03 @ 7:39 PM
Study NCT ID: NCT02464657
Status: COMPLETED
Last Update Posted: 2021-10-07
First Post: 2015-06-03
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia View
None Acute Myeloid Leukemia View
None Myelodysplastic Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Leukemia View
None Acute myeloid leukemia View
None AML View
None Myelodysplastic Syndrome View
None MDS View
None High-risk View
None Nivolumab View
None BMS-936558 View
None Opdivo View
None Idarubicin View
None Idamycin View
None Cytarabine View
None Ara-C View
None Cytosar View
None DepoCyt View
None Cytosine Arabinosine Hydrochloride View
None Solu-Medrol View
None Methylprednisolone View
None Depo-Medrol View
None Medrol View
None Dexamethasone View
None Decadron View